Abstract Number: 0131 • ACR Convergence 2024
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…Abstract Number: 1880 • ACR Convergence 2024
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…Abstract Number: 2616 • ACR Convergence 2024
Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…Abstract Number: 1888 • ACR Convergence 2024
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Background/Purpose: People with immune-mediated inflammatory diseases (IMIDs) may be more vulnerable to severe COVID-19 outcomes. COVID-19 vaccination is a key element in mitigating this risk.…Abstract Number: 2666 • ACR Convergence 2024
The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans
Background/Purpose: Several case reports and case series of idiopathic inflammatory myositis (IIM) following COVID-19 vaccination have been reported. This study evaluated the association of prior…Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…Abstract Number: 0718 • ACR Convergence 2024
Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an…Abstract Number: 1897 • ACR Convergence 2024
People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
Background/Purpose: Post-Acute Sequelae of SARS-CoV-2 (PASC) include new or worsening of existing symptoms 3 months or more after SARS-CoV-2 infection. We have shown that vaccination…Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…Abstract Number: 1907 • ACR Convergence 2024
Community-Engaged Curriculum Development Using Racial Justice and Biomedical Lenses to Address COVID-19 Vaccine Hesitancy in Black Individuals with Rheumatologic Conditions
Background/Purpose: Despite the efficacy of COVID-19 vaccines and the benefits for individuals with rheumatic conditions, racial inequities in uptake persist. We initiated a trial that…Abstract Number: 0172 • ACR Convergence 2024
Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies
Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
- 1
- 2
- 3
- …
- 38
- Next Page »